Proteomics and pancreatic cystic neoplasms: a pilot study

Use of proteomics to differentiate between benign and potentially malignant pancreatic cystic neoplasms: a pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN10626053

Enrollment

Registered

2010-06-10

Start date

2009-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic disease Digestive System

Interventions

Prospective collection of pancreatic cystic fluid in patients undergoing open pancreatic surgery aimed at removing the cystic neoplams. Cystic fluid samples collected by direct puncture and submitted

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with pancreatic cystic neoplasms as demonstrated by CT scan planned for open surgery 2. Each patient gave his/her informed consent before surgery

Exclusion criteria

Exclusion criteria: 1. Age < 18 years old 2. Pregnant women

Design outcomes

Primary

Measure	Time frame
To help find specific protein markers to better differentiate between benign and potentially malignant pancreatic cystic neoplams	—

Secondary

Measure	Time frame
To correlate results of the proteomic analysis to pancreatic histologic staining of surgical samples	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026